These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10999985)

  • 1. Community-acquired pneumonia in elderly patients and length of hospitalization.
    Masotti L; Ceccarelli E; Cappelli R; Barabesi L; Forconi S
    Arch Intern Med; 2000 Sep; 160(17):2678-9. PubMed ID: 10999985
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
    Brown RB; Iannini P; Gross P; Kunkel M
    Chest; 2003 May; 123(5):1503-11. PubMed ID: 12740267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
    Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
    Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
    van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
    Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Halpern MT; Cifaldi MA
    Clin Infect Dis; 2004 Jul; 39(1):144-5; author reply 145-6. PubMed ID: 15206068
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire?
    Waterer GW
    Chest; 2003 May; 123(5):1328-9. PubMed ID: 12740239
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia.
    van der Eerden MM; Boersma WG
    Eur Respir J; 2009 Aug; 34(2):521. PubMed ID: 19648530
    [No Abstract]   [Full Text] [Related]  

  • 12. [Start treatment of community-acquired pneumonia in outpatients and in hospitalized patients].
    Budanov SV
    Antibiot Khimioter; 2001; 46(10):25-34. PubMed ID: 11881190
    [No Abstract]   [Full Text] [Related]  

  • 13. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
    Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
    Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [When does pneumonia belong in the hospital -- and when not. Community-acquired -- healed by ambulatory care?].
    MMW Fortschr Med; 2003 Mar; 145(10):12-3. PubMed ID: 12688019
    [No Abstract]   [Full Text] [Related]  

  • 15. Do fluoroquinolones actually increase mortality in community-acquired pneumonia?
    Agarwal R
    Crit Care; 2006 Feb; 10(1):403; author reply 403. PubMed ID: 16469131
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluating the impact of an antimicrobial stewardship program on the length of stay of immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired pneumonia: A quasi-experimental study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Am J Infect Control; 2016 May; 44(5):e73-9. PubMed ID: 26899527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of deviation from guidelines on the outcome of community-acquired pneumonia.
    Menéndez R; Ferrando D; Vallés JM; Vallterra J
    Chest; 2002 Aug; 122(2):612-7. PubMed ID: 12171840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals.
    Dudas V; Hopefl A; Jacobs R; Guglielmo BJ
    Ann Pharmacother; 2000 Apr; 34(4):446-52. PubMed ID: 10772428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals.
    Nie XM; Li YS; Yang ZW; Wang H; Jin SY; Jiao Y; Metersky ML; Huang Y
    Clin Microbiol Infect; 2018 Jun; 24(6):658.e1-658.e6. PubMed ID: 28970157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia.
    Singanayagam A; Aliberti S; Cillóniz C; Torres A; Blasi F; Chalmers JD
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28890433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.